01. Ghadah Alrehaili

The impact of lumacaftor-ivacaftor on health outcomes in Canadians with cystic fibrosis.

2 Comments

  • Andrea Gershon says:

    Interesting work

  • Matthew Binnie says:

    Nice work. It seems concerning that there was no appreciable change in lung function in the overall CF population and no reduction in exacerbations. Does this mean the drug needs to be targeted to specific subgroups, e.g. patients with severe disease? Should we be paying for it?
    What about hospitalizations?
    Have you tried stratifying by genotype?

Leave a Reply

Your email address will not be published. Required fields are marked *